




Instance: composition-en-533640e2b33051c3986eeb9c67d13b2c
InstanceOf: CompositionUvEpi
Title: "Composition for aflunov Package Leaflet"
Description:  "Composition for aflunov Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp13a63ff8a7c270592a46c3bb1277f533)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - aflunov"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What AFLUNOV is and what it is used for </li>
<li>What you need to know before you receive  AFLUNOV </li>
<li>How AFLUNOV is given </li>
<li>Possible side effects </li>
<li>How to store AFLUNOV </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What aflunov is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What aflunov is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>AFLUNOV is a vaccine for use in adults from 18 onwards, intended to be given in the context of 
outbreaks of zoonotic influenza viruses (coming from birds) with pandemic potential to prevent flu 
caused by H5N1 viruses similar to the vaccine strain reported in section 6. Zoonotic influenza viruses occasionally infect humans, and can cause disease ranging from mild upper 
respiratory infection (fever and cough) to rapid progression to severe pneumonia, acute respiratory 
distress syndrome, shock and even death. Human infections are primarily caused by contact with 
infected animals, but do not spread easily between people. </p>
<p>AFLUNOV is intended also to be given when there is anticipation of a possible pandemic due to the 
same or a similar strain. </p>
<p>When a person is given the vaccine, the immune system (the body s natural defence system) will 
produce its own protection (antibodies) against the disease. None of the ingredients in the vaccine 
can cause flu. </p>
<p>As with all vaccines, AFLUNOV may not fully protect all persons who are vaccinated. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take aflunov"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take aflunov"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>You should not receive AFLUNOV: </p>
<ul>
<li>if you have previously had a sudden life-threatening allergic reaction to any ingredient of 
AFLUNOV (listed in section 6) or to any of the substances that may be present in trace amounts 
as follows: egg and chicken protein, ovalbumin, formaldehyde, kanamycin and neomycin 
sulphate (antibiotics), hydrocortisone or cetyltrimethylammonium bromide (CTAB). Signs of an 
allergic reaction may include itchy skin rash, shortness of breath and swelling of the face or 
tongue. However, in a pandemic situation, it may be appropriate for you to be vaccinated with 
AFLUNOV provided that appropriate medical treatment is immediately available in case of an 
allergic reaction. </li>
</ul>
<p>Warnings and precautions </p>
<p>Talk to your doctor or nurse before having this vaccine </p>
<ul>
<li>
<p>if you have had any allergic reaction to any ingredient contained in the vaccine, to egg and 
chicken protein, ovalbumin, formaldehyde, kanamycin and neomycin sulphate (antibiotics), 
hydrocortisone or cetyltrimethylammonium bromide (CTAB) (see section 6. Further 
information); </p>
</li>
<li>
<p>if you have a severe infection with fever (over 38 C). If this applies to you then your 
vaccination will usually be postponed until you are feeling better. A minor infection such as a 
cold should not be a problem, but your doctor or nurse should advise whether you could still be 
vaccinated with AFLUNOV; </p>
</li>
<li>
<p>if you are having a blood test to look for evidence of infection with certain viruses. In the first 
few weeks after vaccination with AFLUNOV the results of these tests may not be correct. Tell 
the doctor requesting these tests that you have recently been given AFLUNOV. </p>
</li>
<li>
<p>in the presence of immune deficiencies AFLUNOV may be administered but a protective 
immune response may not be elicited. </p>
</li>
</ul>
<p>Please inform your doctor or nurse if you have a bleeding problem or bruise easily. </p>
<p>Fainting can occur following, or even before, any needle injection. Therefore tell the doctor or nurse if 
you fainted with a previous injection. </p>
<p>AFLUNOV may not fully protect everyone who is vaccinated, especially elderly subjects and those 
with weakened immune systems, such as HIV patients, or those with underlying long term medical 
problems, such as diabetes, lung disease or heart problems. Tell your doctor if you have a weak 
immune system or an underlying long term medical problem.  </p>
<p>In any of these cases, TELL YOUR DOCTOR OR NURSE, as vaccination may not be recommended, 
or may need to be delayed. </p>
<p>Other medicines and AFLUNOV </p>
<p>Tell your doctor or nurse if you are taking or have recently taken or might take any other medicines, 
including medicines obtained without a prescription or have recently received any other vaccine. </p>
<p>Data obtained in adults showed that AFLUNOV can be given at the same time as non-adjuvanted 
seasonal influenza vaccines. There is no information on administration of AFLUNOV with non-
influenza vaccines. If administration of AFLUNOV with other vaccines can not be avoided, the 
vaccines should be injected into separate limbs. In such cases, you should be aware that the side 
effects may be more intense. </p>
<p>Pregnancy and breast-feeding </p>
<p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask 
your doctor or nurse for advice before receiving this vaccine. Your doctor needs to assess the benefits 
and potential risks of giving you the vaccine.   </p>
<p>Driving and using machines </p>
<p>Some effects mentioned under section 4.  Possible side effects  may affect the ability to drive or use 
machines. </p>
<p>AFLUNOV contains sodium and potassium. </p>
<p>AFLUNOV contains less than 1 mmol sodium (23 mg) and less than 1 mmol of potassium (39 mg) 
per 0.5 ml dose, i.e. essentially sodium- and potassium-free. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take aflunov"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take aflunov"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Your doctor or nurse will administer the vaccine in accordance with official recommendations. 
The vaccine will be injected into the muscles of the upper arm (deltoid muscle). The vaccine should 
never be given into a vein. </p>
<p>Adults from 18 onwards: 
One dose of 0.5 ml will be given. A second dose of 0.5 ml should be given after an interval of 
at least 3 weeks. </p>
<p>There is limited experience in elderly over 70 years of age. </p>
<p>Use in children </p>
<p>Children from 6 months to 17 years of age 
There is limited experience in children between 6 months and 17 years of age. Vaccination is currently 
not recommended in this age group. </p>
<p>Children aged less than 6 months of age<br />
Vaccination is currently not recommended in this age group. </p>
<p>If you have any further questions on the use of this medicinal product, ask your doctor or nurse. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, AFLUNOV can cause side effects, although not everybody gets them. </p>
<p>Allergic reactions may occur following vaccination, in rare cases leading to shock. Doctors are aware 
of this possibility and have emergency treatment available for use in such cases. </p>
<p>The side effects listed below have occurred with AFLUNOV in clinical studies in adults, including 
the elderly: </p>
<p>Very common (affects more than 1 user in 10): 
* Pain at the site of injection 
* Hardening of the skin at the injection site 
* Injection site redness<br />
* Injection site swelling 
* Aching muscles 
* Headache 
* Fatigue. 
* Generally feeling unwell 
* Shivering </p>
<p>Common (affects 1 to 10 users in 100): 
* Brusing of the skin at the injection site 
* Aching joints 
* Fever and nausea 
* Sweating 
Rare (affects 1 to 10 users in 10.000): 
* Anaphylaxis (severe allergic reactions). </p>
<p>These side effects usually disappear within 1-2 days without treatment. If they persist, CONSULT 
YOUR DOCTOR. </p>
<p>Undesirable effects in patients with underlying long term medical problems such as diabetes, lung 
disease or heart problems and weakened immune systems (immunocompromised) such as HIV 
patients 
Nausea, aching joints, diarrhoea and loss of appetite were reported very commonly in this population. 
In addition, vomiting was commonly reported.   </p>
<p>Side effects from clinical study in children (6 months to 17 years of age) 
General side effects reported very commonly in the 6 months to 35 months of age group were 
injection site redness, muscle ache, irritability and unusual crying. Very commonly reported reactions 
in the 36 months to 17 years of age group were pain, headache and fatigue. </p>
<p>Other rare side effects observed after routine use: 
The side effects listed below have occurred in the days or weeks after vaccination with another 
vaccine called Focetria H1N1v similar to AFLUNOV. These side effects may occur with AFLUNOV.  </p>
<ul>
<li>Generalised skin reactions including  </li>
<li>Itching </li>
<li>Urticaria (hives) </li>
<li>Rash or swelling of the skin and mucous membranes </li>
<li>
<p>Angioedema (abnormal swelling of the skin, usually around the eyes, lips, tongue, hands 
or feet, due to an allergic reaction). </p>
</li>
<li>
<p>Disorders of the gut such as  </p>
</li>
<li>Nausea </li>
<li>Vomiting </li>
<li>Abdominal pain  </li>
<li>
<p>Diarrhoea </p>
</li>
<li>
<p>Headache, dizziness, drowsiness, fainting. </p>
</li>
<li>
<p>Neurological disorders such as  </p>
</li>
<li>Severe stabbing or throbbing pain along one or more nerves </li>
<li>Tingling </li>
<li>Fits </li>
<li>
<p>Neuritis (inflammation of nerves) </p>
</li>
<li>
<p>Swollen lymph nodes, palpitations (irregular or forceful heart beat), tachycardia (faster than 
normal heart beat), weakness, pain in the extremities, cough and asthenia (unusual weakness). </p>
</li>
<li>
<p>Allergic reactions possibly with shortness of breath, wheezing, swelling of the throat, or leading 
to a dangerous decrease of blood pressure, which, if untreated, may lead to shock. Doctors are 
aware of this possibility and have emergency treatment available for use in such cases. </p>
</li>
</ul>
<p>Data in children and adolescents suggest a slight decrease in side effects after the second dose of the 
vaccine, with no increase in rates of fever. </p>
<p>In addition, the side effects listed below have occurred in the days or weeks after vaccination with 
vaccines given routinely every year to prevent seasonal flu. These side effects may occur with 
AFLUNOV. </p>
<ul>
<li>Low blood platelet count which can result in bleeding or bruising. </li>
<li>Vasculitis (inflammation of the blood vessels which can cause skin rashes, joint pain and kidney 
problems) </li>
<li>Erythema multiforme (type of allergic skin reaction that occurs in response to medications, 
infections, or illness). </li>
<li>Neurological disorders such as encephalomyelitis (inflammation of the central nervous system), 
and a type of paralysis known as Guillain-Barr  Syndrome. </li>
<li>swelling, pain and redness at the injection site extending to more than 10 cm and lasting more 
than one week (Injection site cellulitis-like reaction) </li>
<li>extensive swelling of injected limb lasting more than one week. </li>
</ul>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not 
listed in this leaflet. You can also report side effects directly via the national reporting system listed 
in Appendix V. By reporting side effects, you can help provide more information on the safety of 
this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store aflunov"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store aflunov"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this vaccine out of the sight and reach of children. </p>
<p>Do not use AFLUNOV after the expiry date which is stated on the carton and the label. The expiry 
date refers to the last day of that month. </p>
<p>Store in a refrigerator (2 C - 8 C).<br />
Do not freeze.<br />
Store in the original package in order to protect from light. </p>
<p>Do not throw any medicines via wastewater or household waste. Ask your pharmacist how to throw 
away medicines you no longer use. These measures will help to protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What AFLUNOV contains </p>
<ul>
<li>Active Substance: 
Influenza virus surface antigens (haemagglutinin and neuraminidase)* of strain: </li>
</ul>
<p>A/turkey/Turkey/1/2005 (H5N1)-like strain (NIBRG-23) (clade 2.2.1) 7.5 micrograms** 
per 0.5 ml dose </p>
<ul>
<li>
<p>propagated in fertilised hens  eggs from healthy chicken flocks 
** 
expressed in microgram haemagglutinin. </p>
</li>
<li>
<p>Adjuvant MF59C.1: 
The vaccine contains per 0.5 ml 9.75 mg squalene, 1.175 mg polysorbate 80, 1.175 mg sorbitan 
trioleate, 0.66 mg sodium citrate and 0.04 mg citric acid.  </p>
</li>
<li>
<p>Other ingredients: 
The other ingredients are: sodium chloride, potassium chloride, potassium dihydrogen 
phosphate, disodium phosphate dihydrate, magnesium chloride hexahydrate, calcium 
chloride dihydrate and water for injections. </p>
</li>
</ul>
<p>What AFLUNOV looks like and contents of the pack </p>
<p>AFLUNOV is a suspension for injection in a pre-filled syringe. 
The suspension is a milky-white liquid. 
It is provided in a ready-to-use pre-filled syringe, containing a single dose of 0.5 ml for injection. </p>
<p>Not all pack sizes may be marketed. </p>
<p>Marketing Authorisation Holder and Manufacturer </p>
<p>Marketing Authorisation Holder 
Seqirus S.r.l. 
Via del Pozzo 3/A, S. Martino 
53035 Monteriggioni (SI) 
Italy. </p>
<p>Manufacturer 
Seqirus Netherlands B.V. 
Paasheuvelweg 1105BJ Amsterdam 
Netherlands </p>
<p>This leaflet was last revised in {MM/YYYY} </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-533640e2b33051c3986eeb9c67d13b2c
InstanceOf: CompositionUvEpi
Title: "Composition for aflunov Package Leaflet"
Description:  "Composition for aflunov Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp13a63ff8a7c270592a46c3bb1277f533)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - aflunov"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen: </p>
<ol>
<li>Virkning og anvendelse </li>
<li>Det skal du vide, før du får AFLUNOV </li>
<li>Sådan får du AFLUNOV </li>
<li>Bivirkninger </li>
<li>Opbevaring </li>
<li>Pakningsstørrelser og yderligere oplysninger </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What aflunov is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What aflunov is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>AFLUNOV er en vaccine til brug til voksne fra 18 år og derover. Den er beregnet til at blive givet i 
forbindelse med udbrud af zoonotiske influenzavira (der kommer fra fugle) med pandemisk potentiale 
til forebyggelse af influenza forårsaget af H5N1-vira, der svarer til vaccinestammen, der er anført i 
punkt 6. Zoonotiske influenzavira inficerer af og til mennesker og kan forårsage sygdom, der spænder fra en let 
infektion i de øvre luftveje (feber og hoste) til hurtig udvikling til kraftig lungebetændelse, akut 
respiratorisk distress syndrom, shock og endog dødsfald. Infektioner hos mennesker opstår primært 
ved kontakt med inficerede dyr og spredes ikke let mellem mennesker. </p>
<p>AFLUNOV er også beregnet til at blive givet, når der er forventning om en mulig pandemi som følge 
af den samme eller en tilsvarende stamme. </p>
<p>Når en person får vaccinen, vil immunsystemet (kroppens naturlige forsvar) skabe sin egen beskyttelse 
(antistoffer) mod sygdommen. Ingen af ingredienserne i vaccinen kan give influenza. </p>
<p>Som med alle vacciner er det ikke sikkert, at AFLUNOV beskytter alle vaccinerede personer 
fuldstændigt. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take aflunov"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take aflunov"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Få ikke AFLUNOV: </p>
<ul>
<li>hvis du tidligere har haft en pludselig, livstruende allergisk reaktion over for en af 
ingredienserne i AFLUNOV (angivet i pkt. 6) eller nogen af de stoffer, der kan være spor af 
i vaccinen: ægge- og kyllingeprotein, ovalbumin, formaldehyd, kanamycin og neomycinsulfat 
(antibiotika), hydrocortison eller cetyltrimethylammoniumbromid (CTAB). Kendetegnene ved 
en allergisk reaktion kan være kløende hududslæt, åndenød og hævet ansigt eller tunge. I en 
pandemisk situation kan det dog være hensigtsmæssigt for dig at blive vaccineret med 
AFLUNOV under forudsætning af, at der er adgang til passende, akut medicinsk behandling, 
hvis det skulle blive nødvendigt i tilfælde af en allergisk reaktion. </li>
</ul>
<p>Advarsler og forsigtighedsregler </p>
<p>Kontakt lægen eller sundhedspersonalet, før du får vaccinen </p>
<ul>
<li>
<p>hvis du har haft en allergisk reaktion over for en af de ingredienser, der findes i vaccinen, 
ægge- og kyllingeprotein, ovalbumin, formaldehyd, kanamycin og neomycinsulfat (antibiotika), 
hydrocortison eller cetyltrimethylammoniumbromid (CTAB) (se pkt. 6. Yderligere oplysninger) </p>
</li>
<li>
<p>hvis du har en alvorlig infektion med feber (over 38 °C). Hvis dette gælder for dig, vil din 
vaccination som regel blive udsat, indtil du har det bedre. En mindre infektion, såsom 
en forkølelse, er normalt ikke nogen hindring, men din læge eller sygeplejerske afgør, om du 
alligevel kan vaccineres med AFLUNOV </p>
</li>
<li>
<p>hvis du skal have taget en blodprøve for at afgøre, om du har bestemte virusinfektioner. 
Resultaterne af disse blodprøver vil muligvis ikke være korrekte i de første uger, efter at du er 
blevet vaccineret med AFLUNOV. Hvis lægen foreslår disse blodprøver, skal du fortælle ham 
eller hende, at du for nylig har fået AFLUNOV </p>
</li>
<li>
<p>i tilfælde af immundefekter kan der gives AFLUNOV, men det er ikke sikkert, at der 
fremkaldes et beskyttende immunrespons. </p>
</li>
</ul>
<p>Fortæl venligst din læge eller sundhedspersonalet, hvis du har blødningsproblemer eller nemt får blå 
mærker. </p>
<p>Besvimelse kan opstå efter, eller endda før, enhver injektion med en kanyle. De skal derfor fortælle 
det til lægen eller sygeplejersken, hvis De tidligere er besvimet i forbindelse med en injektion. </p>
<p>AFLUNOV giver muligvis ikke fuld beskyttelse til alle, der vaccineres, især ældre personer, og 
personer med svækket immunforsvar, såsom HIV-patienter, eller personer med underliggende 
langvarige medicinske problemer, såsom diabetes, lungesygdom eller hjerteproblemer. Fortæl lægen, 
hvis du har et svagt immunforsvar eller et underliggende langvarigt medicinsk problem.  </p>
<p>Hvis noget af ovenstående gælder for dig, SKAL DU FORTÆLLE DET TIL LÆGEN ELLER 
SUNDHEDSPERSONALET, da det kan være, at vaccination ikke anbefales, eller at den skal 
udskydes. </p>
<p>Brug af anden medicin sammen med AFLUNOV </p>
<p>Fortæl det altid til lægen eller sundhedspersonalet, hvis du bruger anden medicin eller har brugt det for 
nylig. Dette gælder også medicin, som ikke er købt på recept. </p>
<p>Resultater fra forsøg med voksne viste, at AFLUNOV kan gives samtidig med ikke-adjuveret 
sæsoninfluenzavaccine. Der er ingen oplysninger om brug af AFLUNOV sammen med vacciner, som 
ikke er influenzavacciner. Hvis det ikke kan undgås at give AFLUNOV samtidig med andre vacciner, 
skal vaccinerne indsprøjtes i to forskellige lemmer. I sådanne tilfælde skal du være opmærksom på, at 
bivirkningerne kan være mere intense. </p>
<p>Graviditet og amning </p>
<p>Hvis du er gravid eller ammer, har mistanke om, at du er gravid eller planlægger at blive gravid, 
skal du spørge din læge eller sundhedspersonalet til råds, før du får vaccinen. Din læge må vurdere 
fordelene og de mulige risici ved at give dig vaccinen. </p>
<p>Trafik- og arbejdssikkerhed </p>
<p>Nogle af de virkninger, som er nævnt under pkt. 4 "Bivirkninger", kan muligvis påvirke evnen til 
at føre motorkøretøj og betjene maskiner. </p>
<p>AFLUNOV indeholder natrium og kalium </p>
<p>AFLUNOV indeholder mindre end 1 mmol natrium (23 mg) og mindre end 1 mmol kalium (39 mg) 
per 0,5 ml dosis, dvs. at det i det væsentlige er natrium- og kaliumfrit. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take aflunov"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take aflunov"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Lægen eller sygeplejersken vil give dig vaccinen i overensstemmelse med de officielle retningslinjer. 
Vaccinen vil blive sprøjtet ind i overarmsmusklen (deltamusklen). Vaccinen må aldrig gives i en 
blodåre. </p>
<p>Voksne fra 18 år og derover: 
Der gives en dosis på 0,5 ml. Der bør gives endnu en dosis på 0,5 ml efter et interval på mindst 3 uger. </p>
<p>Erfaringerne hos ældre over 70 år er begrænsede. </p>
<p>Brug til børn </p>
<p>Børn fra 6 måneder til 17 år 
Erfaringerne hos børn i alderen 6 måneder til 17 år er begrænsede. Vaccinering anbefales i øjeblikket 
ikke hos denne aldersgruppe. </p>
<p>Børn under 6 måneder 
Vaccinering anbefales i øjeblikket ikke hos denne aldersgruppe. </p>
<p>Spørg lægen eller sundhedspersonalet, hvis der er noget, du er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>AFLUNOV kan som al anden medicin give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Der kan opstå allergiske reaktioner efter vaccinationen, som i sjældne tilfælde kan medføre shock. 
Lægerne kender til denne risiko, og de har derfor udstyr til akut behandling til brug i disse tilfælde. </p>
<p>Bivirkningerne nedenfor er opstået under kliniske studier med AFLUNOV hos voksne, 
inklusive ældre: </p>
<p>Meget almindelig (forekommer hos 1 bruger ud af 10): </p>
<ul>
<li>
<p>Smerter på injektionsstedet </p>
</li>
<li>
<p>Hårdhed på injektionsstedet </p>
</li>
<li>
<p>Rødme på injektionsstedet </p>
</li>
<li>
<p>Hævelse på injektionsstedet </p>
</li>
<li>
<p>Muskelsmerter </p>
</li>
<li>
<p>Hovedpine </p>
</li>
<li>
<p>Træthed </p>
</li>
<li>
<p>Generel utilpashed </p>
</li>
<li>
<p>Kulderystelser </p>
</li>
</ul>
<p>Almindelig (forekommer hos 1 til 10 brugere ud af 100): </p>
<ul>
<li>
<p>Blå mærker ved injektionsstedet </p>
</li>
<li>
<p>Ledsmerter </p>
</li>
<li>
<p>Feber og kvalme </p>
</li>
<li>
<p>Svedtendens </p>
</li>
</ul>
<p>Sjælden (forekommer hos 1 til 10 brugere ud af 10.000): </p>
<ul>
<li>Anafylaktisk shock (kraftig allergisk reaktion) </li>
</ul>
<p>Disse bivirkninger forsvinder som regel inden for 1-2 dage uden behandling. SØG LÆGE, hvis 
bivirkningerne varer ved. </p>
<p>Birvirkninger hos patienter med underliggende langvarige medicinske problemer, såsom diabetes, 
lungesygdom eller hjerteproblemer, og svækket immunforsvar, såsom HIV-patienter 
Kvalme, ledsmerter, diarré og appetitløshed er meget hyppigt rapporterede bivirkninger i denne 
population. Endvidere er opkastning hyppigt rapporteret. </p>
<p>Bivirkninger fra kliniske studier hos børn (6 måneder til 17 år) 
Meget almindelige bivirkninger for aldersgruppen 6 til 35 måneder var rødme på injektionsstedet, 
muskelsmerter, irritabilitet og usædvanlig gråd. Meget almindelige bivirkninger i 
aldersgruppen 36 måneder til 17 år var smerter, hovedpine og træthed. </p>
<p>Andre sjældne bivirkninger, som er set efter rutinemæssig brug: 
Nedenstående bivirkninger er forekommet i dagene og ugerne efter vaccination med Focetria 
H1N1v-vaccine, som er en anden vaccine, der ligner AFLUNOV. Disse bivirkninger kan måske også 
forekomme med AFLUNOV. </p>
<ul>
<li>
<p>Generelle hudreaktioner inklusive </p>
</li>
<li>
<p>Kløe </p>
</li>
<li>
<p>Nældefeber </p>
</li>
<li>
<p>Udslæt eller hævelse af hud og slimhinder </p>
</li>
<li>
<p>Angioødem (unormal hævelse af huden, sædvanligvis omkring øjne, af læber, tunge, 
hænder eller fødder, som følge af en allergisk reaktion) </p>
</li>
<li>
<p>Mave-tarmlidelser såsom: </p>
</li>
<li>
<p>Kvalme </p>
</li>
<li>
<p>Opkastning </p>
</li>
<li>
<p>Mavesmerter </p>
</li>
<li>
<p>Diarré </p>
</li>
<li>
<p>Hovedpine, svimmelhed, døsighed, besvimelse </p>
</li>
<li>
<p>Neurologiske lidelser som </p>
</li>
<li>
<p>Stikkende eller pulserende smerte langs en eller flere nerver </p>
</li>
<li>
<p>Prikken </p>
</li>
<li>
<p>Krampe </p>
</li>
<li>
<p>Neuritis (nervebetændelse) </p>
</li>
<li>
<p>Hævede lymfekirtler, hjertebanken (uregelmæssige eller kraftige hjerteslag), takykardi 
(hurtigere hjerteslag end normalt), svaghed, smerte i arme/ben og hoste, asteni (usædvanlig 
kraftesløshed) </p>
</li>
<li>
<p>Allergiske reaktioner, muligvis med åndenød, hivende vejrtrækning, hævelse af svælget eller 
førende til et farligt fald i blodtrykket, som kan føre til shock, hvis det ikke behandles. Lægerne 
kender til denne risiko, og de har derfor udstyr til akut behandling til brug i disse tilfælde. </p>
</li>
</ul>
<p>Data for børn og unge antyder et svagt fald i bivirkninger efter den anden dosis af vaccinen, uden 
øgning i forekomsten af feber. </p>
<p>Herudover er bivirkningerne i listen nedenfor set i dagene eller ugerne efter vaccination med vacciner, 
som gives rutinemæssigt hvert år for at forebygge sæsoninfluenza. Disse bivirkninger kan forekomme 
med AFLUNOV. </p>
<ul>
<li>
<p>Lavt blodpladeantal, som kan medføre blødning eller blå mærker </p>
</li>
<li>
<p>Vaskulitis (betændelse i blodkarrene, hvilket kan forårsage hududslæt, ledsmerter og 
nyreproblemer) </p>
</li>
<li>
<p>Erythema multiforme (en slags allergisk hudreaktion, der forekommer som respons på 
lægemidler, infektioner eller sygdomme) </p>
</li>
<li>
<p>Neurologiske lidelser som encephalomyelitis (betændelse i centralnervesystemet) og en slags 
lammelse, som kaldes Guillain-Barrés syndrom  </p>
</li>
<li>
<p>Hævelse, smerter og rødme på injektionsstedet, der dækker mere end 10 cm og varer mere end 
én uge (cellulitislignende reaktion på injektionstedet) </p>
</li>
<li>
<p>Kraftig hævelse af armen eller benet, der er injiceret, som varer mere end én uge </p>
</li>
</ul>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge eller sygeplejerske. Dette gælder også mulige 
bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan også indberette 
bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i Appendiks 
V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information om 
sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store aflunov"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store aflunov"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar denne vaccine utilgængeligt for børn. </p>
<p>Brug ikke AFLUNOV efter den udløbsdato, der står på pakningen. Udløbsdatoen (efter Exp) er den 
sidste dag i den nævnte måned. </p>
<p>Opbevares i køleskab (2 °C - 8 °C). 
Må ikke nedfryses. 
Opbevares i den originale yderpakning for at beskytte mod lys. </p>
<p>Spørg på apoteket, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke smide 
medicinrester i afløbet, toilettet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>AFLUNOV indeholder </p>
<ul>
<li>Aktivt stof: 
Influenzavirus-overfladeantigener (hæmagglutinin og neuraminidase)* fra stammen: </li>
</ul>
<p>A/turkey/Turkey/1/2005 (H5N1)-lignende stamme (NIBRG-23) (clade 2.2.1)   7,5 mikrogram** 
pr. 0,5 ml dosis </p>
<ul>
<li>formeret i befrugtede hønseæg fra sunde hønsehold </li>
</ul>
<p>** 
udtrykt som mikrogram hæmagglutinin. </p>
<ul>
<li>
<p>Adjuvans MF59C.1: 
Vaccinen indeholder pr. 0,5 ml 9,75 mg squalen, 1,175 mg polysorbat, 1,175 mg 
sorbitantrioleat, 0,66 mg natriumcitrat og 0,04 mg citronsyre. </p>
</li>
<li>
<p>Øvrige indholdsstoffer: 
Øvrige indholdsstoffer: natriumchlorid, kaliumchlorid, kaliumdihydrogenphosphat, 
dinatriumphosphatdihydrat, magnesiumchloridhexahydrat, calciumchloriddihydrat og vand til 
injektioner. </p>
</li>
</ul>
<p>Udseende og pakningsstørrelser </p>
<p>AFLUNOV er en injektionsvæske, suspension i fyldt injektionssprøjte. 
Suspensionen er en mælkehvid væske. 
Den leveres i en injektionssprøjte klar til brug med en enkelt dosis på 0,5 ml til injektion. </p>
<p>Ikke alle pakningsstørrelser er nødvendigvis markedsført. </p>
<p>Indehaver af markedsføringstilladelsen og fremstiller: </p>
<p>Indehaver af markedsføringstilladelsen 
Seqirus S.r.l. 
Via del Pozzo 3/A, S. Martino 
53035 Monteriggioni (SI) 
Italien. </p>
<p>Fremstiller 
Seqirus Netherlands B.V. 
Paasheuvelweg 1105BJ Amsterdam 
Holland </p>
<p>Denne indlægsseddel blev senest ændret {MM/ÅÅÅÅ}. </p>
<p>Du kan finde yderligere information om AFLUNOV på Det europæiske Lægemiddelagenturs 
hjemmeside: http://www.ema.europa.eu </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-533640e2b33051c3986eeb9c67d13b2c
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for aflunov Package Leaflet for language en"
Description: "ePI document Bundle for aflunov Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-533640e2b33051c3986eeb9c67d13b2c"
* entry[0].resource = composition-en-533640e2b33051c3986eeb9c67d13b2c

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp533640e2b33051c3986eeb9c67d13b2c"
* entry[=].resource = mp533640e2b33051c3986eeb9c67d13b2c
                            
                    
Instance: bundlepackageleaflet-da-533640e2b33051c3986eeb9c67d13b2c
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for aflunov Package Leaflet for language da"
Description: "ePI document Bundle for aflunov Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-533640e2b33051c3986eeb9c67d13b2c"
* entry[0].resource = composition-da-533640e2b33051c3986eeb9c67d13b2c

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp533640e2b33051c3986eeb9c67d13b2c"
* entry[=].resource = mp533640e2b33051c3986eeb9c67d13b2c
                            
                    



Instance: mp533640e2b33051c3986eeb9c67d13b2c
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product AFLUNOV suspension for injection in pre-filled syringe."
Description: "AFLUNOV suspension for injection in pre-filled syringe."
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/10/658/001-002"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "AFLUNOV suspension for injection in pre-filled syringe."
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 533640e2b33051c3986eeb9c67d13b2cListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "aflunov"

* status = #current
* mode = #working

* title = "List of all ePIs associated with aflunov"

* subject = Reference(mp13a63ff8a7c270592a46c3bb1277f533)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#aflunov "aflunov"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-533640e2b33051c3986eeb9c67d13b2c) // aflunov en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-533640e2b33051c3986eeb9c67d13b2c) // aflunov da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-533640e2b33051c3986eeb9c67d13b2c
InstanceOf: List

* insert 533640e2b33051c3986eeb9c67d13b2cListRuleset
    